Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

With this reimbursement, approximately 45 people with cystic fibrosis in Australia will become eligible for a CFTR modulator for the first time –– ...

Vertex Pharmaceuticals (NASDAQ ... As the company expands beyond its core CF franchise into new therapeutic areas such as pain management and rare diseases, investors and analysts are closely ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...

In 10 years, there will probably be a different set of trending topics on The Street, but those changes won't stop the market ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company focusing on developing and commercializing therapies for treating cystic fibrosis (CF). The one-month return of Vertex ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ET David M. Altshuler - Executive VP & Chief Scientific Officer ...

Vertex Pharmaceuticals (NASDAQ ... This performance underscores the strength of Vertex's core CF franchise, which continues to be the primary driver of revenue and growth. Want deeper insights?